HRP20070527T3 - Benzothiazole derivatives for the treatment of diabetes - Google Patents

Benzothiazole derivatives for the treatment of diabetes

Info

Publication number
HRP20070527T3
HRP20070527T3 HR20070527T HRP20070527T HRP20070527T3 HR P20070527 T3 HRP20070527 T3 HR P20070527T3 HR 20070527 T HR20070527 T HR 20070527T HR P20070527 T HRP20070527 T HR P20070527T HR P20070527 T3 HRP20070527 T3 HR P20070527T3
Authority
HR
Croatia
Prior art keywords
group
diabetes
treatment
insulin resistance
amino
Prior art date
Application number
HR20070527T
Other languages
English (en)
Croatian (hr)
Inventor
Gaillard Pascale
Gotteland Jean-Pierre
Vitte Pierre-Alain
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of HRP20070527T3 publication Critical patent/HRP20070527T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HR20070527T 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes HRP20070527T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
HRP20070527T3 true HRP20070527T3 (en) 2007-12-31

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070527T HRP20070527T3 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Country Status (17)

Country Link
US (2) US20070088017A1 (https=)
EP (1) EP1696909B1 (https=)
JP (1) JP5021307B2 (https=)
AT (1) ATE378047T1 (https=)
AU (1) AU2004271740B2 (https=)
CA (1) CA2534314C (https=)
CY (1) CY1107820T1 (https=)
DE (1) DE602004010178T2 (https=)
DK (1) DK1696909T3 (https=)
ES (1) ES2297494T3 (https=)
HR (1) HRP20070527T3 (https=)
IL (1) IL174250A (https=)
NO (1) NO20061600L (https=)
PL (1) PL1696909T3 (https=)
PT (1) PT1696909E (https=)
SI (1) SI1696909T1 (https=)
WO (1) WO2005025567A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100121057A1 (en) * 2007-04-17 2010-05-13 Merck Serono Sa Process for the Preparation of Piperazine Benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
CN115887434B (zh) * 2022-11-23 2024-12-24 四川大学 具有抗氧化作用的药物用于制备治疗多囊卵巢综合征药物的用途
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
ATE340572T1 (de) * 2001-12-07 2006-10-15 Applied Research Systems Benzazole derivate zur behandlung von scleroderma
WO2003091249A1 (en) * 2002-04-25 2003-11-06 Applied Research Systems Ars Holding N.V. Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Also Published As

Publication number Publication date
EP1696909A1 (en) 2006-09-06
JP5021307B2 (ja) 2012-09-05
US20070088017A1 (en) 2007-04-19
PL1696909T3 (pl) 2008-04-30
JP2007505083A (ja) 2007-03-08
CA2534314C (en) 2012-11-13
IL174250A0 (en) 2006-08-01
DE602004010178D1 (de) 2007-12-27
AU2004271740A1 (en) 2005-03-24
CY1107820T1 (el) 2013-06-19
CA2534314A1 (en) 2005-03-24
SI1696909T1 (sl) 2008-02-29
ATE378047T1 (de) 2007-11-15
DK1696909T3 (da) 2008-01-02
US20140107116A1 (en) 2014-04-17
AU2004271740B2 (en) 2010-10-28
HK1096594A1 (en) 2007-06-08
PT1696909E (pt) 2007-12-21
NO20061600L (no) 2006-04-07
ES2297494T3 (es) 2008-05-01
IL174250A (en) 2011-01-31
WO2005025567A1 (en) 2005-03-24
DE602004010178T2 (de) 2008-09-11
EP1696909B1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
HRP20070527T3 (en) Benzothiazole derivatives for the treatment of diabetes
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
TW200617001A (en) Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same
BR0313290A (pt) Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produção
BRPI0413555A (pt) composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto
NO20053748L (no) Pyrrolopyridazinderivater.
AR041299A1 (es) Derivados de pirrolidona como inhibidores de maob
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
RU2005129999A (ru) Диарилциклоалкильные производные, способы их получения и их применение в качестве лекарственного средства
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
IL166103A0 (en) Pyrrolidine derivatives and their use
TW200634001A (en) Novel compounds
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
NO20061599L (no) Benzoksazol acetonitriler
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
DE60227008D1 (de) Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen
ATE431148T1 (de) Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme
DK1755583T3 (da) Anvendelse af neboglamin til behandling af skizofreni
DK1614684T3 (da) Diaminderivat, produktionsproces og antioxidantlægemiddel
TH1701007595A (th) อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์
TH68181A (th) อนุพันธ์ 1,3-ซับสทิทิวเทดไซโคลแอลคิลที่มีหมู่เฮเทอโรไซคลิคเป็นส่วนใหญ่ซึ่งมีฤทธิ์เป็นกรด กรรมวิธีสำหรับเตรียมสารเหล่านี้และการใช้สารเหล่านี้เป็นยารักษาโรค
EP1757596A4 (en) N-PHENYLACRYLOYL SUBSTITUTED TYROSINE DERIVATIVES AS AGONISTS OF HPPAR ALPHA AND HPPAR GAMMA